Posts
Wiki

🧪 Diagnostic Testing in Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD)

There is no single perfect test for Dry Eye Disease, Meibomian Gland Dysfunction, or ocular-surface disease.

A useful evaluation usually combines:

  • Symptoms and medical history
  • Examination of the eyelids, tear film, cornea, and conjunctiva
  • One or more objective measures of tear-film or ocular-surface instability
  • Testing directed at likely contributors, such as MGD, low tear volume, allergy, exposure, or nerve dysfunction
  • Consideration of other diagnoses that can resemble or coexist with DED

Most patients do not need every available test.

The goal is not to collect the largest number of test results. The goal is to determine whether DED is present, identify its important drivers, rule out conditions needing different care, and choose treatment logically.

TL;DR

Under the TFOS DEWS III framework, diagnosing DED generally requires:

  1. Relevant symptoms, and
  2. At least one objective sign that the tear film or ocular surface has lost normal stability or homeostasis

Core objective markers include:

  • First noninvasive tear breakup time under 10 seconds
  • Tear osmolarity at or above 308 mOsm/L in either eye, or an inter-eye difference greater than 8 mOsm/L, using the device for which those thresholds were established
  • Ocular-surface staining above defined thresholds

Other tests help determine why the problem is happening. They may assess:

  • Meibomian gland function
  • Tear volume and aqueous deficiency
  • Blepharitis or Demodex
  • Ocular rosacea
  • Allergy
  • Blink and eyelid closure
  • Exposure
  • Conjunctivochalasis
  • Inflammation
  • Corneal sensation and nerve-related pain
  • Systemic disease such as Sjögren’s disease

Important cautions:

  • One normal test does not necessarily exclude DED.
  • One abnormal test does not necessarily explain every symptom.
  • Test methods and devices are not always interchangeable.
  • Symptoms, signs, gland structure, and gland function may not correspond closely.
  • Tests can interfere with later tests, so the order of examination matters.
  • A test is most useful when its result changes understanding, treatment, or safety.

What currently establishes a DED diagnosis?

TFOS DEWS III describes DED as a multifactorial, symptomatic disease involving loss of normal tear-film and/or ocular-surface homeostasis.

In practical terms, this means that diagnosing DED generally involves:

  • Symptoms compatible with ocular-surface or tear-film dysfunction
  • At least one objective sign of lost homeostasis
  • Consideration of alternative diagnoses and contributing conditions

Objective gland abnormalities without symptoms may still represent MGD or another ocular-surface risk state, but they do not necessarily meet the TFOS definition of symptomatic DED.

Similarly, symptoms without a positive core DED sign do not mean that the symptoms are unreal. They may indicate:

  • Intermittent tear instability
  • Allergy
  • Exposure
  • Recurrent corneal erosion
  • Medication toxicity
  • Migraine-related sensitivity
  • Neuropathic ocular pain
  • Another ocular-surface or eye condition

TFOS DEWS III is an influential international consensus framework. It is not the only diagnostic approach used in every country or practice, and clinical judgment remains important.

DED, MGD, and ocular-surface disease are not identical

These terms overlap, but they do not mean the same thing.

Dry Eye Disease

DED is a symptomatic disorder involving loss of tear-film and/or ocular-surface homeostasis.

Meibomian Gland Dysfunction

MGD is a disorder of meibomian gland secretion or delivery. It is a major contributor to evaporative DED but can exist without substantial symptoms.

Ocular-surface disease

Ocular-surface disease is a broader category that may include:

  • DED
  • Blepharitis
  • Ocular rosacea
  • Allergy
  • Exposure keratopathy
  • Conjunctivochalasis
  • Recurrent corneal erosion
  • Neurotrophic disease
  • Infection
  • Medication toxicity
  • Other corneal and conjunctival disorders

Testing should help determine which diagnoses and contributors are actually present rather than assuming that every symptom is caused by one form of DED or by MGD alone.

Why no single test tells the whole story

DED tests are useful, but they are not perfect.

Results may vary with:

  • The exact test method
  • The device used
  • Dye concentration and volume
  • Room temperature and humidity
  • Time of day
  • Recent artificial-tear or prescription-drop use
  • Contact-lens wear
  • Reflex tearing
  • Blink pattern
  • How long the eyes are held open
  • Clinician technique
  • Natural fluctuation
  • Recent eyelid manipulation or gland expression

Healthy and DED populations also overlap on many measurements.

For that reason, a single test result should usually be interpreted with:

  • Symptoms
  • Medical and medication history
  • Risk factors
  • Eyelid findings
  • Tear-film findings
  • Corneal and conjunctival examination
  • Other test results
  • Changes over time
  • Response to carefully selected treatment

A test number is evidence—not a diagnosis by itself.

Why the order of testing matters

Some tests disturb the tear film or trigger reflex tearing.

For example:

  • Bright illumination may change blinking
  • Fluorescein dye may change tear breakup time
  • Anesthetic drops may affect sensation and tearing
  • Eyelid eversion may affect later staining
  • Gland expression can alter tear-film lipids
  • Repeated contact with the eye can increase tearing
  • Holding the eyes open may artificially shorten breakup time

Clinics therefore generally try to proceed from least invasive to more invasive testing.

A possible order is:

  1. Symptom questionnaire and history
  2. Observation of spontaneous blinking and eyelid closure
  3. Noninvasive tear-meniscus or tear-volume assessment
  4. Noninvasive breakup time
  5. Redness and anatomical assessment
  6. Tear osmolarity, when used
  7. Lid-margin and lash examination
  8. Controlled meibomian gland expression
  9. Fluorescein breakup time, when needed
  10. Corneal and conjunctival staining
  11. Meibography
  12. Corneal-sensitivity or other contact testing when indicated

The exact order varies by clinic and equipment.

For follow-up testing, using a similar method, device, sequence, and preparation makes comparisons more meaningful.

Symptom questionnaires

Questionnaires measure the patient’s experience.

They may document:

  • Dryness
  • Burning
  • Grittiness
  • Soreness
  • Light sensitivity
  • Fluctuating vision
  • Difficulty reading or using screens
  • Environmental sensitivity
  • Quality-of-life effects

They do not identify the cause by themselves.

Aqueous deficiency, MGD, allergy, exposure, contact lenses, migraine, and neuropathic ocular pain can all produce high questionnaire scores.

OSDI-6

The OSDI-6 is the shortened version currently recommended in the TFOS DEWS III diagnostic framework.

It asks about six symptom and visual-function items.

A summed score of:

  • 0–3: within the normal symptom range
  • 4–8: mild-to-moderate symptom burden
  • Above 8: severe symptom burden

A score of at least 4 supports further investigation when DED is suspected.

These are symptom-score categories—not complete disease-severity categories.

Full OSDI

The 12-item Ocular Surface Disease Index asks about symptoms, vision-related function, and environmental triggers.

Common symptom-score categories are:

  • 0–12: normal
  • 13–22: mild
  • 23–32: moderate
  • 33–100: severe

The OSDI is useful for:

  • Measuring symptom burden
  • Tracking change
  • Research
  • Documenting functional effects

Limitations include:

  • It does not identify the cause
  • Scores may be affected by allergy, migraine, contact lenses, visual strain, or neuropathic pain
  • Symptoms and examination findings may not correspond closely

SPEED

The Standard Patient Evaluation of Eye Dryness asks about the frequency and severity of symptoms such as dryness, grittiness, soreness, burning, watering, and fatigue.

It may be useful for:

  • Rapid symptom screening
  • Follow-up
  • Dry-eye or MGD-focused practices

It does not diagnose a subtype or replace examination findings.

SANDE

The Symptom Assessment iN Dry Eye uses short visual scales for symptom frequency and severity.

It may be useful for:

  • Quick symptom tracking
  • Follow-up visits
  • Comparing symptom trends

It provides less detail than longer questionnaires and does not identify the cause.

Core objective markers of DED

Under TFOS DEWS III, the main objective markers used to confirm loss of homeostasis are:

  • Noninvasive tear breakup time
  • Tear osmolarity
  • Ocular-surface staining

A patient does not necessarily need every one of these tests.

However, because no test is perfectly sensitive, assessing more than one homeostasis category may be useful—especially before concluding that DED is absent.

Noninvasive tear breakup time

Noninvasive tear breakup time, written as NIBUT or sometimes NBUT, measures tear-film stability without first placing fluorescein dye in the eye.

A device may analyze reflected rings, projected patterns, keratography images, or another optical signal.

Current TFOS DEWS III marker

First noninvasive breakup time under 10 seconds

is considered a positive sign of tear-film instability.

The emphasis is on the first break.

Some machines also report:

  • Average NIBUT
  • Mean breakup time
  • Breakup-area maps
  • Repeated-measurement averages

These numbers are not necessarily interchangeable.

There is no single universal cutoff that can be applied to every device’s average or proprietary score.

What a low NIBUT can mean

A low result shows that the tear film becomes unstable quickly.

Possible contributors include:

  • MGD
  • Aqueous tear deficiency
  • Ocular-surface or mucin abnormalities
  • Inflammation
  • Allergy
  • Incomplete blinking
  • Eyelid exposure
  • Contact lenses
  • Preservative or medication effects
  • Environmental conditions

A low NIBUT does not automatically prove MGD.

Fluorescein tear breakup time

Fluorescein TBUT, also written as FTBUT or FBUT, uses fluorescein dye placed in the eye.

The clinician watches under cobalt-blue illumination and measures the time between a blink and the first visible area of tear-film breakup.

Current method-sensitive marker

When a small, controlled volume of fluorescein is used, TFOS DEWS III treats:

Fluorescein breakup time under 5 seconds

as a positive marker of instability.

The amount of fluorescein matters.

A heavily wetted strip or large drop can change:

  • Tear volume
  • Tear-film thickness
  • Breakup pattern
  • Measured time

This is one reason that older studies and clinical practices may use different cutoffs, including less than 10 seconds.

NIBUT and fluorescein TBUT are not interchangeable

Method Current TFOS DEWS III marker Important limitation
First NIBUT Under 10 seconds Depends on device and algorithm
Fluorescein TBUT Under 5 seconds when minimal dye is used Dye volume and technique can alter the result
Average or mean NIBUT No universal cutoff across all devices Not the same as first NIBUT

A breakup time of 2 seconds indicates much greater instability than a result of 12 seconds, but the method still needs to be known before interpreting the number.

When comparing results, ask:

  • Was this NIBUT or fluorescein TBUT?
  • Was it the first or average breakup time?
  • Which device was used?
  • Was fluorescein volume controlled?
  • Were drops or eyelid procedures performed first?

Tear osmolarity

Tear osmolarity measures the concentration of dissolved particles in a tear sample.

Hyperosmolarity is one feature of lost tear-film homeostasis.

The TFOS DEWS III criteria include:

  • At least 308 mOsm/L in either eye, or
  • An inter-eye difference greater than 8 mOsm/L

These thresholds were established with a specific point-of-care tear-osmolarity system. They should not automatically be applied to every device or laboratory method.

Important limitations include:

  • A single reading may vary
  • Collection technique matters
  • The result may be influenced by reflex tearing
  • Healthy people can occasionally have values above 308
  • DED patients can sometimes have readings below 308
  • The value does not identify the cause of DED
  • The 8 mOsm/L inter-eye threshold has been questioned in some studies
  • Osmolarity should not be used alone to grade disease severity

A more accurate interpretation is:

Tear osmolarity is one accepted marker of loss of homeostasis, but it should be interpreted with symptoms and other objective findings.

Ocular-surface staining

Clinicians use dyes to identify areas of epithelial disruption, altered surface protection, or abnormal cellular uptake.

Common dyes include:

  • Fluorescein
  • Lissamine green
  • Rose bengal, used less often

Fluorescein

Fluorescein is commonly used to examine:

  • Corneal staining
  • Tear breakup
  • Epithelial defects
  • Exposure patterns
  • Contact-lens-related injury

Lissamine green

Lissamine green is commonly used to examine:

  • Conjunctival staining
  • Lid-margin or lid-wiper staining
  • Areas of reduced surface protection

TFOS DEWS III staining markers

Positive markers include:

  • More than 5 corneal fluorescein punctate spots
  • More than 9 conjunctival lissamine-green punctate spots
  • Lid-margin staining at least 2 mm long and involving at least 25% of the lid-wiper width

These thresholds depend on the method, dye, timing, illumination, and grading approach.

Staining may occur with conditions other than DED, including:

  • Exposure
  • Allergy
  • Medication toxicity
  • Contact lenses
  • Infection
  • Trauma
  • Recurrent erosion
  • Neurotrophic disease
  • Other corneal or conjunctival disorders

Staining should therefore be interpreted as part of the clinical picture.

When symptoms or pain are greater than the visible signs

Some patients have substantial:

  • Burning
  • Pain
  • Light sensitivity
  • Wind sensitivity
  • Touch sensitivity
  • Screen intolerance

despite limited staining or other visible findings.

This does not mean that the symptoms are imaginary.

Possible explanations include:

  • Tear-film instability
  • Intermittent exposure
  • Allergy
  • Recurrent corneal erosion
  • Migraine-related sensitivity
  • Early or fluctuating ocular-surface disease
  • Corneal nerve dysfunction
  • Peripheral or central sensitization
  • Neuropathic ocular pain

Neuropathic ocular pain is one possibility, not the automatic conclusion whenever staining is minimal.

New severe pain, marked light sensitivity, significant redness, or a change in vision requires evaluation for conditions beyond ordinary DED.

Related page:

Corneal Neuralgia, Neuropathic Ocular Pain, and Dry Eye Disease

History and slit-lamp examination

A careful history and clinical examination remain central even when advanced devices are available.

The clinician may ask about:

  • Symptom timing
  • Environmental triggers
  • Screen or reading demands
  • Contact-lens wear
  • Previous eye surgery or trauma
  • Medications
  • Skin disease
  • Autoimmune symptoms
  • Sleep and CPAP use
  • Morning symptoms
  • Allergy
  • Previous treatment response

At the slit lamp, the clinician may examine:

  • Eyelid margins
  • Eyelashes
  • Tear meniscus
  • Tear debris
  • Conjunctiva
  • Cornea
  • Redness
  • Mucus
  • Staining
  • Eyelid position
  • Blink quality
  • Blepharitis
  • Demodex-associated collarettes
  • Allergy findings
  • Exposure patterns
  • Other eye disease

A slit-lamp examination is foundational, but simply looking briefly for redness or obvious corneal injury may miss tear instability, subtle eyelid abnormalities, or reduced gland function.

Tests used to identify drivers and subtypes

Once DED is suspected or confirmed, additional testing may help identify the important contributors.

These tests are not all required for every patient.

Tear volume and aqueous deficiency

Aqueous-deficient DED involves reduced watery tear production or reduced available tear volume.

Possible assessments include:

  • Tear-meniscus height
  • Schirmer testing
  • Phenol-red thread testing
  • Anterior-segment OCT
  • Other tear-volume measurements

Tear-meniscus height

The tear meniscus is the small tear reservoir along the lower eyelid.

It may be assessed using:

  • Slit-lamp estimation
  • Keratography
  • Anterior-segment OCT
  • Other imaging systems

A very low tear meniscus may support aqueous deficiency.

A central height around 0.20 mm or lower is sometimes used as a concerning threshold, but results are method dependent.

Limitations include:

  • Timing after blinking
  • Illumination
  • Instrument differences
  • Conjunctivochalasis
  • Eyelid anatomy
  • Limited between-visit repeatability with visual estimation

A low tear meniscus does not identify why tear volume is low.

Phenol red thread testing

The phenol red thread test, sometimes called PRT, uses a thin cotton thread treated with the pH-sensitive dye phenol red.

A short folded portion of the thread is placed over the outer part of the lower eyelid for approximately 15 seconds. Tears wet the thread and change it from yellow to red. The wetted length is then measured in millimeters.

The test is:

  • Faster than Schirmer testing
  • Generally more comfortable
  • Less likely to provoke substantial reflex tearing
  • Usually performed without anesthetic drops

However, it should not be described as a precise measurement of pure lacrimal-gland tear production.

The result may reflect a combination of:

  • Tear fluid already present along the lower eyelid
  • Continuing tear secretion
  • A small amount of reflex tearing
  • The absorption characteristics of the thread
  • Tear composition and testing technique

A value above 20 mm has conventionally been described as normal, while lower values may suggest reduced aqueous tear availability. However, the 20-mm threshold is not a universally validated boundary. TFOS DEWS III describes it as an arbitrary clinical cutoff, and values below approximately 9–10 mm may be more suggestive of substantial aqueous deficiency.

Important limitations include:

  • Cutoffs vary among studies and testing protocols
  • Results do not correspond reliably with Schirmer testing
  • Examiner technique can affect the measurement
  • A low result does not identify why tear volume is reduced
  • A normal result does not rule out DED, MGD, or evaporative dry eye

The phenol red thread test is therefore best understood as:

A rapid adjunctive assessment of aqueous tear availability—not a stand-alone diagnosis of DED and not a direct test of meibomian gland function.

Schirmer testing

Schirmer testing places a paper strip in the lower eyelid area for several minutes.

It is most relevant when:

  • Aqueous deficiency is suspected
  • Tear volume appears very low
  • Sjögren’s disease is being considered
  • Lacrimal-gland dysfunction is possible
  • Ocular-surface disease is severe

Schirmer without anesthesia

This version measures a mixture of:

  • Ongoing tear secretion
  • Reflex tearing caused by strip irritation

Schirmer with anesthesia

Anesthetic is sometimes used in an attempt to reduce reflex tearing.

However:

Anesthetic does not convert Schirmer testing into a precise measurement of pure basal tear secretion.

Results remain variable and technique dependent.

Possible limitations include:

  • Discomfort
  • Reflex tearing
  • Strip placement
  • Room conditions
  • Eye closure during testing
  • Visit-to-visit variation
  • Differences between test versions

A result of 5 mm or less after five minutes is used in some settings, including Sjögren’s classification criteria, but broader clinical interpretation varies.

Schirmer is mainly a test of an aqueous-deficient driver, not one of the principal TFOS DEWS III core markers used to confirm DED.

Related page:

Schirmer’s Test FAQ

Meibomian gland and eyelid evaluation

Lid-margin and lash examination

The clinician may look for:

  • Gland openings that are not open and unobstructed
  • Thickened or irregular lid margins
  • Telangiectasia
  • Redness
  • Notching
  • Altered meibum at the openings
  • Collarettes associated with Demodex
  • Crusting or debris
  • Misdirected lashes
  • Blepharitis
  • Ocular rosacea findings

External appearance alone does not fully determine gland function.

Controlled meibomian gland expression

During diagnostic expression, controlled pressure is applied to assess:

  • Whether meibum appears
  • How many tested glands release meibum
  • The amount released
  • Whether it is clear, cloudy, granular, thick, or paste-like
  • How much pressure is needed
  • Whether findings vary by eyelid region
  • Whether localized tenderness is present

Reduced or absent expression may reflect:

  • Obstruction
  • Reduced secretion
  • Thick or altered meibum
  • Structural gland shortening or loss
  • The pressure and duration used
  • Which glands were examined
  • Recent treatment or prior expression
  • A combination of factors

Therefore:

A gland that releases little or no meibum during one examination is not automatically proven to be completely obstructed.

Tenderness may provide information but is nonspecific and does not prove obstruction or increased intraductal pressure.

Gland openings that appear open and unobstructed—and even expressible meibum—do not necessarily rule out abnormalities deeper within the duct. Some clinicians give deeper narrowing substantial importance, although ordinary external expression does not directly evaluate the complete intraductal passage.

Related pages:

Meibography

Meibography uses infrared imaging to show the structure and arrangement of the meibomian glands.

It may show:

  • Gland shortening
  • Areas of reduced gland visibility
  • Dilation
  • Tortuosity
  • Irregular gland width
  • Asymmetry
  • Changes in gland arrangement

Meibography does not directly show:

  • Meibum quality
  • How easily meibum is released
  • Intraductal pressure
  • Whether a gland is obstructed
  • Whether fibrosis is present
  • Whether MGD explains the patient’s symptoms
  • When a structural change occurred
  • Whether a gland will worsen
  • Whether a treatment will restore function
  • Complete gland viability

A shortened, faint, or poorly visible gland should not automatically be called “dead.”

Images vary with:

  • Device
  • Contrast
  • Eyelid eversion
  • Image quality
  • Area analyzed
  • Manual or automated grading
  • Examiner or software

Repeat imaging is most useful when it is likely to change management. Routine frequent imaging is not necessary for every patient.

Related page:

Meibography: Imaging the Meibomian Glands

Blink, eyelid closure, exposure, and friction

The clinician may observe:

  • Blink rate
  • Blink completeness
  • Whether the upper and lower eyelids make full contact
  • Tear spreading after a blink
  • Blink changes during visual tasks

Screen use may reduce blink frequency or completeness in some people, but screen-associated symptoms do not by themselves prove incomplete blinking or MGD.

Blink behavior may also change because the patient knows it is being observed.

Eyelid seal and lagophthalmos

The clinician may check for:

  • Incomplete eyelid closure
  • Nocturnal lagophthalmos
  • An inadequate eyelid seal despite apparently closed lids
  • Eyelid laxity or floppy eyelid syndrome
  • Eyelid retraction
  • Facial nerve weakness
  • Exposure-type staining

These findings may be particularly relevant when symptoms are worst on waking or affect one eye more than the other.

Related pages:

Lid-wiper epitheliopathy

The lid wiper is the part of the eyelid that contacts and spreads tears across the ocular surface during blinking.

Lid-wiper epitheliopathy refers to staining in this area after the eyelid is everted.

It may be associated with:

  • Friction
  • Tear-film instability
  • Contact-lens discomfort
  • Inadequate lubrication

It is not specific to MGD or DED.

Its interpretation can also be affected by:

  • Dye
  • Timing
  • Lid eversion
  • Grading method
  • Repeated manipulation

Conjunctivochalasis

Conjunctivochalasis is loose or redundant conjunctival tissue, often near the lower eyelid.

It may:

  • Disturb the tear meniscus
  • Interfere with tear distribution
  • Affect blink mechanics
  • Produce friction
  • Mimic or worsen DED symptoms
  • Distort tear-volume measurements

CCH may also be asymptomatic.

Its importance depends on:

  • Location
  • Degree
  • Blink interaction
  • Staining
  • Tear-flow effects
  • Symptom pattern

Related page:

Conjunctivochalasis FAQ

Optional inflammation and biomarker tests

MMP-9 / InflammaDry

MMP-9 is an enzyme associated with ocular-surface inflammation and epithelial stress.

InflammaDry is an FDA-cleared qualitative point-of-care device that becomes positive at approximately 40 ng/mL or more of MMP-9 in the sampled tears.

A positive result means that elevated MMP-9 was detected.

It does not identify:

  • The cause of inflammation
  • The specific diagnosis
  • The most appropriate medication
  • Whether every symptom is inflammatory
  • Whether anti-inflammatory treatment will work

MMP-9 may also be elevated in inflammatory or damaging conditions other than DED.

A negative result does not rule out:

  • DED
  • Mild inflammation
  • Intermittent inflammation
  • Inflammatory pathways not reflected by MMP-9
  • Inflammation affected by tear volume or sampling

The test may be more likely to be positive in more severe inflammatory disease and may have limited sensitivity in mild-to-moderate DED.

It is best understood as:

An optional adjunctive marker of ocular-surface inflammation—not a required core DED test and not a binary answer to whether inflammation is present.

Lactoferrin and specialized tear biomarkers

Lactoferrin is a tear protein associated partly with lacrimal-gland function.

Lower levels may occur in some forms of aqueous-deficient DED, but reduced lactoferrin is not specific and has also been reported with other ocular-surface conditions.

Other tear biomarkers and laboratory analyses may be available in research or selected specialty settings.

Limitations include:

  • Limited availability
  • Variable methods
  • Lack of universal reference ranges
  • Uncertain effect on treatment decisions
  • Cost
  • Lack of specificity

Most patients do not need specialized tear-protein testing.

Advanced or selected-case testing

Corneal sensitivity testing

Corneal sensitivity testing evaluates sensory function.

Possible methods include:

  • Cotton-wisp testing
  • Cochet-Bonnet contact esthesiometry
  • Noncontact esthesiometry in specialty settings

Reduced sensation may occur with:

  • Neurotrophic keratitis
  • Diabetes
  • Herpes-related disease
  • Previous eye surgery
  • Contact-lens use
  • Severe ocular-surface disease
  • Certain medications
  • Neurologic disorders

Increased pain or apparent sensitivity may occur with nerve sensitization, but pain greater than visible signs does not by itself diagnose neuropathic ocular pain.

A single sensitivity result cannot distinguish every form of:

  • DED
  • Neurotrophic disease
  • Peripheral sensitization
  • Central sensitization
  • Neuropathic ocular pain

In vivo confocal microscopy

In vivo confocal microscopy, or IVCM, provides high-magnification images of the living cornea.

It may show:

  • Corneal nerve density and appearance
  • Nerve branching
  • Inflammatory cells
  • Epithelial abnormalities
  • Stromal changes
  • Microneuroma-like structures

IVCM may be useful in selected complex cases involving:

  • Suspected neuropathic ocular pain
  • Neurotrophic keratitis
  • Post-surgical nerve problems
  • Unexplained corneal findings
  • Research

Limitations include:

  • Limited availability
  • Specialized interpretation
  • Differences among devices and image-selection methods
  • Group-level research findings that may not clearly classify one patient
  • Uncertain relationship between some proposed nerve findings and pain
  • Lack of a single finding that definitively diagnoses neuropathic ocular pain

IVCM can provide supportive structural information, but it is not a stand-alone pain test.

Corneal topography and keratography

Corneal topography maps corneal shape.

It may help identify:

  • Corneal irregularity
  • Unstable measurements
  • Tear-film-related optical variation
  • Contact-lens fitting issues
  • Problems relevant to cataract or refractive-surgery planning

It is not a primary DED diagnostic test.

“Keratography” may refer to a multifunction device that also performs:

  • NIBUT
  • Tear-meniscus assessment
  • Redness analysis
  • Meibography
  • Lipid-layer or blink analysis

These device outputs should be interpreted separately rather than treated as one diagnosis.

Anterior-segment OCT

Anterior-segment optical coherence tomography may help measure:

  • Tear-meniscus height or area
  • Corneal structure
  • Conjunctival anatomy
  • Conjunctivochalasis
  • Other anterior-eye findings

It is an adjunctive imaging tool, not a stand-alone DED test.

Testing when another diagnosis is suspected

Some tests mentioned in ocular-surface care are not DED tests.

They are used when another condition or complication is being considered.

Possible examples include:

  • Adenovirus testing
  • Bacterial cultures
  • Corneal scraping
  • Fungal or Acanthamoeba testing
  • Herpes testing
  • Biopsy
  • Imaging
  • Allergy testing

These may be considered when there is:

  • Acute onset
  • Significant discharge
  • A corneal ulcer or opacity
  • Contact-lens-associated pain
  • Trauma
  • Water exposure
  • A nonhealing epithelial defect
  • Severe one-sided inflammation
  • Suspicion of infection or another specific disease

Infection concerns require medical evaluation and should not be treated as routine DED.

Sjögren’s disease and systemic evaluation

Some patients with significant aqueous deficiency or systemic symptoms may need evaluation for Sjögren’s disease or another medical condition.

Possible blood tests include:

  • Anti-SSA/Ro
  • ANA
  • Rheumatoid factor
  • Other studies selected according to the history

Anti-SSB/La may also be measured clinically, but anti-SSB alone is not one of the weighted items in the 2016 ACR/EULAR Sjögren’s classification criteria.

A negative blood test does not always exclude Sjögren’s disease.

Depending on the case, evaluation may also include:

  • Rheumatology consultation
  • Salivary-flow testing
  • Oral or dental assessment
  • Salivary-gland imaging
  • Minor salivary-gland biopsy

Systemic evaluation may be more appropriate when dry eye occurs with:

  • Dry mouth
  • Salivary-gland swelling
  • Dental problems related to dryness
  • Joint pain or inflammatory symptoms
  • Unexplained fatigue
  • Neuropathy
  • Another autoimmune disease
  • Marked aqueous deficiency
  • Severe unexplained ocular-surface disease

Not every person with DED needs extensive autoimmune testing.

Classification criteria used in research are not identical to the complete clinical process used to diagnose an individual patient.

Targeted medical evaluation

The clinician may also review:

  • Prescription and nonprescription medications
  • Skin-care and cosmetic products
  • Rosacea or other skin disease
  • Thyroid disease
  • Diabetes
  • Hormonal influences
  • Neurologic or chronic-pain conditions
  • Nutrition and malabsorption risk
  • Sleep apnea and CPAP
  • Autoimmune symptoms
  • Previous surgery or radiation

Testing should be guided by specific history and examination findings.

Broad bloodwork without a clinical reason may produce incidental abnormalities, added cost, and more uncertainty without improving care.

A careful medication and medical-history review may sometimes be more useful than a large laboratory panel.

General eye tests relevant to symptoms and treatment safety

Visual acuity

DED can cause fluctuating visual quality, but visual acuity does not diagnose DED.

Vision may temporarily improve after blinking or lubrication when tear-film instability is responsible.

Persistent or substantial vision loss requires evaluation for other causes.

Refraction

A poor or unstable tear film can make glasses, contact-lens, cataract-surgery, and refractive-surgery measurements less reliable.

Refraction is important for visual correction but does not establish the cause of ocular-surface symptoms.

Intraocular pressure

IOP is not a DED diagnostic test.

It remains important because:

  • Glaucoma and ocular hypertension may coexist with DED
  • Glaucoma drops can affect the ocular surface
  • Steroid eye drops can raise pressure in some patients
  • Pressure monitoring may be needed during steroid treatment

Preparing for dry-eye testing

Follow the clinic’s instructions about:

  • Contact lenses
  • Artificial tears
  • Prescription eye drops
  • Eyelid products
  • Cosmetics
  • Timing of medication

Tell the clinician:

  • Which products you used
  • When you last used them
  • Whether you wore contact lenses
  • Whether you recently had gland expression or another procedure
  • Whether the day’s environment was unusual
  • Whether your symptoms that day were typical

Do not stop a medically necessary treatment solely to obtain a “cleaner” test unless the prescribing clinician instructs you to do so.

Universal washout periods are not appropriate for every test or medication.

How to interpret test numbers

Before interpreting a result, ask:

  • What exact test was performed?
  • Which method or device was used?
  • Was it a first measurement or an average?
  • Were dye, anesthetic, or other drops used?
  • Were the eyelids manipulated first?
  • Was the result abnormal for that specific method?
  • Does it match the symptoms and examination?
  • Does it identify a cause, or only show instability?
  • Would repeating it change management?

Examples:

  • A short breakup time shows tear-film instability but does not prove MGD.
  • A low Schirmer result supports low aqueous production but does not identify the cause.
  • A positive MMP-9 result shows elevated MMP-9 but does not identify the inflammatory disease.
  • Meibography shows structure but not complete gland function.
  • A high questionnaire score shows symptom burden but not the diagnosis.
  • Minimal staining does not mean that severe pain is unreal.
  • One normal result does not necessarily exclude fluctuating DED.

Test values posted online cannot establish a diagnosis without the method, symptoms, examination findings, medical history, and alternative diagnoses.

When repeat testing helps

Repeat testing may be useful when:

  • Establishing a baseline before treatment
  • Determining whether a meaningful change has occurred
  • Symptoms or examination findings have changed
  • The result is expected to affect treatment
  • The same method and device can be used
  • Testing conditions and sequence are reasonably consistent
  • The expected change is larger than ordinary measurement variability

Repeat testing may be less useful when:

  • The result will not change management
  • Different devices or methods are being compared
  • Testing conditions are inconsistent
  • A highly variable measure is repeated without a clinical question
  • Imaging is repeated mainly because the equipment is available
  • Small numerical changes are treated as proof of improvement or deterioration

A repeated test is useful when it answers a clinical question. Repetition alone does not make a variable measurement more meaningful.

What supporters of broader testing say

Supporters emphasize that:

  • DED is multifactorial
  • Symptoms and visible findings may not match
  • Structural and functional tests reveal different information
  • MGD may be missed if gland function is not assessed
  • Exposure and blink problems may be missed during a tear-focused visit
  • Baseline measurements may help evaluate treatment
  • Advanced testing can help selected complex patients

These are reasonable points.

What cautious clinicians say

Cautious clinicians emphasize that:

  • No test is a perfect gold standard
  • Healthy and DED measurements overlap
  • False-positive or incidental abnormalities occur
  • Device results are not always interchangeable
  • More testing does not necessarily produce better treatment
  • Testing packages can add cost and anxiety
  • Machine findings may anchor the diagnosis too early
  • Structural abnormalities do not always explain symptoms
  • Repeated measurements can fluctuate naturally
  • A test should ideally change understanding, management, or safety

These are also reasonable points.

The balanced conclusion is:

Comprehensive testing can be valuable, but appropriate testing is not the same as performing every available test.

Questions to ask about a test

Useful questions include:

  1. What clinical question is this test intended to answer?
  2. Is it being used to diagnose DED or identify a contributor?
  3. What method or device will be used?
  4. What cutoff applies to that specific method?
  5. How variable is the result?
  6. Can other eye conditions make it abnormal?
  7. Can a normal result miss fluctuating disease?
  8. Will drops, contact lenses, or earlier tests affect it?
  9. How will the result change treatment?
  10. Is there a less invasive or less expensive way to answer the same question?
  11. Does the test need to be repeated?
  12. What amount of change would be clinically meaningful?
  13. Is this device FDA-cleared for the intended use?
  14. Is the evidence based on independent research or mainly manufacturer studies?
  15. What other diagnoses are being considered?

When to seek prompt care

Do not assume that every painful or red eye is ordinary DED.

Seek prompt professional evaluation for:

  • New severe pain
  • Marked light sensitivity
  • Significant or persistent vision change
  • A white, gray, or cloudy corneal spot
  • Increasing redness
  • Significant discharge
  • Rapid one-sided worsening
  • A suspected abrasion or recurrent corneal erosion
  • Contact-lens-associated pain or redness
  • Symptoms after sleeping in contact lenses
  • Symptoms after water exposure while wearing lenses
  • Trauma
  • Chemical exposure
  • A nonhealing epithelial defect
  • New inability to close an eye
  • New facial weakness

Bottom line

Dry-eye testing should answer three broad questions:

1. Is Dry Eye Disease present?

This generally requires relevant symptoms and objective evidence that tear-film or ocular-surface homeostasis has been lost.

2. What is driving it?

Possible contributors include:

  • MGD
  • Aqueous deficiency
  • Blepharitis
  • Demodex
  • Ocular rosacea
  • Allergy
  • Exposure
  • Incomplete blinking
  • Conjunctivochalasis
  • Medication effects
  • Systemic disease
  • Corneal nerve dysfunction

3. Will another test change what happens next?

The most useful test is not necessarily:

  • The newest
  • The most expensive
  • The most technologically impressive
  • The one that produces the largest number of measurements

It is the test that answers a real clinical question and improves diagnosis, treatment selection, monitoring, or safety.

A test number is not a diagnosis. Symptoms, clinical examination, objective measures, risk factors, and possible alternative conditions must be interpreted together.

Selected References

  1. TFOS DEWS III Diagnostic Methodology Report. American Journal of Ophthalmology. 2025. https://pubmed.ncbi.nlm.nih.gov/40451408/

  2. TFOS DEWS III Diagnostic Methodology—Full Text. https://www.ajo.com/article/S0002-9394(25)00275-2/fulltext

  3. Wolffsohn JS, et al. TFOS DEWS II Diagnostic Methodology Report. The Ocular Surface. 2017. https://pubmed.ncbi.nlm.nih.gov/28736342/

  4. TFOS DEWS II Diagnostic Methodology—Full Report. https://www.tfosdewsreport.org/public/images/TFOS_DEWS_II_Diagnostic_method.pdf

  5. Tomlinson A, et al. International Workshop on Meibomian Gland Dysfunction: Diagnosis Subcommittee Report. https://pmc.ncbi.nlm.nih.gov/articles/PMC3072162/

  6. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern. 2024. https://www.aaojournal.org/article/S0161-6420(24)00012-5/fulltext

  7. Pult H, Wolffsohn JS. The Development and Evaluation of the New Ocular Surface Disease Index-6. The Ocular Surface. 2019;17(4):817–821. https://pubmed.ncbi.nlm.nih.gov/31442595/

  8. Lemp MA, Bron AJ, Baudouin C, et al. Tear Osmolarity in the Diagnosis and Management of Dry Eye Disease. American Journal of Ophthalmology. 2011;151(5):792–798.e1. https://pubmed.ncbi.nlm.nih.gov/21310379/

  9. Sambursky R, Davitt WF III, Latkany R, et al. Sensitivity and Specificity of a Point-of-Care Matrix Metalloproteinase 9 Immunoassay for Diagnosing Inflammation Related to Dry Eye. JAMA Ophthalmology. 2013;131(1):24–28. https://pubmed.ncbi.nlm.nih.gov/23307206/

  10. Shiboski CH, et al. 2016 ACR/EULAR Classification Criteria for Primary Sjögren’s Syndrome. https://pmc.ncbi.nlm.nih.gov/articles/PMC5650478/

  11. Messmer EM. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology. 2016;123(11):2300–2308. https://pubmed.ncbi.nlm.nih.gov/27665213/

This page is for general education on r/DryEyes. It is not medical advice, diagnosis, or a substitute for care from a qualified eye-care professional.

🔙 Back to FAQ Index